Table 2.
Characteristics of the patients in the 1.5-hour uptake time group and the SUVmax of the parietal bones and jawbone lesions
| No. | Sex | Age | Jawbone lesions (Cancer) | ARA | MRONJ stage | Jawbone | SUVmax of the parietal bones | SUVmax of the jawbone lesion | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.5 h | 2.0 h | 2.0 h–1.5 h | 1.5 h | 2.0 h | 2.0 h–1.5 h | |||||||
| 21 | F | 73 | MRONJ (BC) | Dmab | 2 | Mandible | 2.65 | 2.74 | 0.10 | 14.32 | 15.51 | 1.19 |
| 22 | F | 57 | MRONJ (BC) | ZA | 1 | Mandible | 2.17 | 1.94 | −0.23 | 6.47 | 6.20 | −0.27 |
| 23 | F | 70 | MRONJ (BC) | Dmab | 2 | Mandible | 1.77 | 1.85 | 0.09 | 5.90 | 6.12 | 0.22 |
| 24 | M | 73 | MRONJ (MM) | Dmab | 2 | Mandible | 1.73 | 1.72 | −0.01 | 13.47 | 15.50 | 2.03 |
| 25 | F | 66 | MRONJ (BC) | ZA | 2 | Maxilla | 2.11 | 2.20 | 0.09 | 6.61 | 7.64 | 1.03 |
| 26 | F | 70 | MRONJ (BC) | Dmab | 2 | Maxilla | 3.00 | 3.00 | 0.00 | 8.23 | 8.16 | −0.07 |
| 27 | M | 80 | MRONJ (LC) | Dmab | 0 | Mandible | 1.55 | 1.59 | 0.04 | 7.58 | 8.44 | 0.86 |
| 28 | F | 70 | MRONJ (BC) | ZA | 2 | Mandible | 2.68 | 2.73 | 0.06 | 6.86 | 7.90 | 1.04 |
| 29 | M | 80 | MRONJ (PC) | ZA | Healed | Mandible | 0.94 | 0.93 | −0.01 | 4.88 | 5.06 | 0.18 |
| 30 | F | 60 | MRONJ (BC) | ZA-Dmab | 2 | Mandible | 1.40 | 1.59 | 0.19 | 5.46 | 5.20 | −0.26 |
| 31 | F | 67 | MRONJ (LC) | Dmab | 2 | Mandible | 1.84 | 1.93 | 0.09 | 4.62 | 5.87 | 1.25 |
| 32 | M | 75 | MRONJ (PC) | Dmab | 3 | Mandible | 1.41 | 1.47 | 0.06 | 8.33 | 9.34 | 1.01 |
| 33 | M | 81 | MRONJ (LC) | Dmab | 2 | Mandible | 1.79 | 1.77 | −0.02 | 10.80 | 12.58 | 1.78 |
| 34 | F | 49 | OOJ | - | - | Maxilla | 2.17 | 2.10 | −0.07 | 5.86 | 6.61 | 0.75 |
| 35 | M | 63 | MRONJ (PC) | Dmab | 2 | Mandible | 1.54 | 1.59 | 0.05 | 10.97 | 12.31 | 1.34 |
| 36 | M | 58 | OOJ | - | - | Mandible | 2.29 | 2.17 | −0.12 | 6.08 | 6.55 | 0.47 |
| 37 | F | 90 | MRONJ (BC) | Dmab | 3 | Mandible | 2.88 | 2.92 | 0.04 | 20.05 | 21.91 | 1.86 |
| 38 | F | 71 | MRONJ (BC) | Dmab | 2 | Mandible | 2.32 | 2.18 | −0.14 | 19.46 | 23.44 | 3.98 |
| 39 | F | 57 | MRONJ (BC) | ZA-Dmab | 3 | Mandible | 1.85 | 1.87 | 0.02 | 5.89 | 6.08 | 0.19 |
| 40 | F | 95 | MRONJ Osteoporosis | IA | 2 | Mandible | 2.18 | 2.29 | 0.11 | 9.50 | 9.93 | 0.43 |
| median | 70 | 2 | 1.98 | 1.93 | 0.04 | 7.22 | 8.03 | 0.94 | ||||
| Q1-Q3 | (62.3–76.3) | (1.68–2.30) | (1.68–2.22) | (−0.01-0.09) | (5.90-10.84) | (6.18–12.38) | (0.21–1.27) | |||||
ARA antiresorptive agent, Dmab denosumab, IA ibandronic acid, SUVmax maximum standardized uptake value, MRONJ medication-related osteonecrosis of the jaw, OOJ odontogenic osteomyelitis of the jaw, Q1 quartile 1, Q3 quartile 3, M male, F female, ZA Zoledronic acid, BC Breast cancer, LC Lung cancer, MM Multiple myeloma, PC Prostate cancer